New breast cancer genetics research from McGill University, Department of Human Genetics discussed

	Tweet

New research, ‘Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent,’ is the subject of a report (see also Breast-Cancer-Genetics.html">Breast Cancer Genetics). According to recent research published in the journal BMC Cancer, “The TP53 polymorphisms Arg72Pro (Ex4+199 G>C) and Ins16 (IVS3+24 ins16) have been proposed to modify risk of breast cancer associated with germline BRCA1 and BRCA2 mutations. Allele frequencies of these polymorphisms were investigated to determine if they modify risk in BRCA mutation carriers in breast cancer cases drawn from French Canadian cancer families, a population shown to exhibit strong founder effects.”

“The frequencies of the TP53 alleles, genotypes and haplotypes of 157 index breast cancer cases comprised of 42 BRCA1 mutation carriers, 57 BRCA2 mutation carriers, and 58 BRCA mutation-negative cases, where each case was drawn from independently ascertained families were compared. The effect of TP53 variants on the age of diagnosis was also investigated for these groups. The TP53 polymorphisms were also investigated in 112 women of French Canadian descent with no personal history of cancer. The BRCA mutation-positive groups had the highest frequency of homozygous carriers of the 72Pro allele compared with mutation-negative group. The TP53 polymorphisms exhibited linkage disequilibrium (p <0.001), where the 72Arg and Ins16minus alleles occurred in strong disequilibrium. The highest frequency of carriers of Ins16minus-72Arg haplotype occurred in the BRCA mutation-negative groups. The BRCA1 mutation carriers homozygous for the 72Pro allele had the youngest ages of diagnosis of breast cancer. 

However none of these observations were statistically significant. In contrast, the BRCA2 mutation carriers homozygous for the 72Pro allele had a significantly older age of diagnosis of breast cancer (p=0.018). Moreover, in this group, the mean age of diagnosis of breast cancer in carriers of the Ins16minus-72Arg haplotype was significantly younger than that of the individuals who did not this carry this haplotype (p=0.009). We observed no significant association of breast cancer risk with TP53 genetic variants based on BRCA1/2 mutation carrier status. Although the small sample size did not permit analysis of all possible haplotypes, we observed that BRCA2 mutation carriers harboring the Ins16minus-72Arg haplotype had a significantly younger mean age of diagnosis of breast cancer,” wrote L. Cavallone and colleagues, McGill University, Department of Human Genetics.

The researchers concluded: “These observations suggest that investigations in a larger French Canadian sample are warranted to further elucidate the effects of TP53 variants on age of diagnosis of breast cancer among BRCA1 and BRCA2 mutation carriers.”

Cavallone and colleagues published their study in BMC Cancer (Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer, 2008;8():96).

For additional information, contact L. Cavallone, McGill University, Dept. of Human Genetics, Montreal, Canada.

The publisher’s contact information for the journal BMC Cancer is: Biomedical Central Ltd., Middlesex House, 34-42 Cleveland St., London W1T 4LB, England.

RELATED STORIES:
Pregnancy cuts breast cancer in mutation carriers   Study suggests newer breast cancer drug may protect heart   Five years on breast cancer drug tamoxifen beats two   Taking tamoxifen to prevent breast cancer can save lives and money   Adding breast exam to mammogram - is it worth it?   Hispanic Women and Breast Cancer: An Understudied Group   Tracking and feedback registry may reduce racial disparities in breast cancer care   Exercise boosts well-being after breast cancer   Treatment May Need to Be Modified for Elderly Brain Cancer Patients   Antibiotic Slows Growth of Bladder, Breast Cancer Cells   Hair Stylists Promote Breast Cancer Prevention Messages to Clients   ‘Stereo’ mammography takes breast imaging to a new dimension   Study shows benefit of finding second tumor early   Waiting for biopsy results may adversely affect health   Breast cancer pill saves few lives, study finds   Scientists uncover new key to the puzzle of hormone therapy and breast cancer   Circulating tumor cells predicted recurrence, death in patients with early-stage breast cancer   Broken genomes behind breast cancers   Mammograms saved lives of women under 50: study   Most women overestimate their breast cancer risk   Genetic Markers, Shortened Radiation Focus of New Breast Cancer Research   Breast Self-Exams Do Not Appear to Reduce Breast Cancer Deaths

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]